FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378905636> ?p ?o ?g. }

• W4378905636 endingPage "175628482311749" @default.
• W4378905636 startingPage "175628482311749" @default.
• W4378905636 abstract "Background: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce. Objective: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD). Design: A nationwide, prospective multicentre extension of a Swedish observational study on VDZ assessing Effectiveness And Healthcare resource utilization in patients with IBD (SVEAH). Methods: After re-consent, data of patients with Crohn’s disease (CD) ( n = 68) and ulcerative colitis (UC) ( n = 46) treated with VDZ were prospectively recorded using an electronic case report form integrated with the Swedish IBD Register (SWIBREG). The primary outcome was clinical remission (defined as Harvey–Bradshaw Index ⩽4 in CD and partial Mayo score ⩽2 in UC) at 104 and 156 weeks in patients with a response and/or remission 12 weeks after starting VDZ. Secondary outcomes included health-related quality of life (HRQoL) and biochemical outcomes. Results: VDZ continuation rates were high at weeks 104 and 156, 88% and 84%, respectively, for CD and 87% and 78%, respectively, for UC. Of the 53 CD patients with a response/remission at 12 weeks, 40 (75%) patients were in remission at 104 weeks and 42 (79%) patients at 156 weeks. For UC, these numbers were 25/31 (81%) and 22/31 (71%), respectively. Improvements were seen in the Short Health Scale ( p < 0.01 for each dimension; CD, n = 51; UC, n = 33) and the EuroQol 5-Dimensions, 5-levels index value ( p < 0.01; CD, n = 39; UC, n = 30). Median plasma-C-reactive protein concentrations (mg/L) decreased from 5 at baseline to 4 in CD ( p = 0.01, n = 53) and from 5 to 4 in UC ( p = 0.03, n = 34) at 156 weeks. Correspondingly, median faecal-calprotectin (µg/g) decreased from 641 to 114 in CD patients ( p < 0.01, n = 26) and from 387 to 37 in UC patients ( p = 0.02, n = 17). Conclusion: VDZ demonstrated high continuation rates and was associated with improvements in clinical outcomes, HRQoL measures and inflammatory markers at 2 and 3 years after treatment initiation in this prospective national SVEAH extension study. Registration: ENCePP registration number: EUPAS22735." @default.
• W4378905636 created "2023-06-01" @default.
• W4378905636 creator A5008368451 @default.
• W4378905636 creator A5011546745 @default.
• W4378905636 creator A5016297911 @default.
• W4378905636 creator A5017335255 @default.
• W4378905636 creator A5019252027 @default.
• W4378905636 creator A5019938824 @default.
• W4378905636 creator A5019960092 @default.
• W4378905636 creator A5024055027 @default.
• W4378905636 creator A5037425566 @default.
• W4378905636 creator A5056439573 @default.
• W4378905636 creator A5057902086 @default.
• W4378905636 creator A5062458709 @default.
• W4378905636 creator A5068091489 @default.
• W4378905636 creator A5070381365 @default.
• W4378905636 creator A5074870098 @default.
• W4378905636 creator A5080579789 @default.
• W4378905636 creator A5091553385 @default.
• W4378905636 date "2023-01-01" @default.
• W4378905636 modified "2023-10-01" @default.
• W4378905636 title "Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study" @default.
• W4378905636 cites W1147871078 @default.
• W4378905636 cites W1991810959 @default.
• W4378905636 cites W2011837830 @default.
• W4378905636 cites W2015250839 @default.
• W4378905636 cites W2022661087 @default.
• W4378905636 cites W2031193040 @default.
• W4378905636 cites W2034795132 @default.
• W4378905636 cites W2041428141 @default.
• W4378905636 cites W2077531651 @default.
• W4378905636 cites W2092863985 @default.
• W4378905636 cites W2096675088 @default.
• W4378905636 cites W2102013054 @default.
• W4378905636 cites W2152026434 @default.
• W4378905636 cites W2162805528 @default.
• W4378905636 cites W2171297959 @default.
• W4378905636 cites W2171341132 @default.
• W4378905636 cites W2274605499 @default.
• W4378905636 cites W2275737843 @default.
• W4378905636 cites W2330470789 @default.
• W4378905636 cites W2427633307 @default.
• W4378905636 cites W2523706394 @default.
• W4378905636 cites W2529617706 @default.
• W4378905636 cites W2551516232 @default.
• W4378905636 cites W2583633660 @default.
• W4378905636 cites W2586374020 @default.
• W4378905636 cites W2623221337 @default.
• W4378905636 cites W2749020449 @default.
• W4378905636 cites W2765680011 @default.
• W4378905636 cites W2800857706 @default.
• W4378905636 cites W2801753207 @default.
• W4378905636 cites W2806806868 @default.
• W4378905636 cites W2809894743 @default.
• W4378905636 cites W2895702868 @default.
• W4378905636 cites W2909741219 @default.
• W4378905636 cites W2928185169 @default.
• W4378905636 cites W2995009999 @default.
• W4378905636 cites W3009768886 @default.
• W4378905636 cites W3082374255 @default.
• W4378905636 cites W3180056052 @default.
• W4378905636 cites W4207003102 @default.
• W4378905636 cites W4226049333 @default.
• W4378905636 doi "https://doi.org/10.1177/17562848231174953" @default.
• W4378905636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37274297" @default.
• W4378905636 hasPublicationYear "2023" @default.
• W4378905636 type Work @default.
• W4378905636 citedByCount "0" @default.
• W4378905636 crossrefType "journal-article" @default.
• W4378905636 hasAuthorship W4378905636A5008368451 @default.
• W4378905636 hasAuthorship W4378905636A5011546745 @default.
• W4378905636 hasAuthorship W4378905636A5016297911 @default.
• W4378905636 hasAuthorship W4378905636A5017335255 @default.
• W4378905636 hasAuthorship W4378905636A5019252027 @default.
• W4378905636 hasAuthorship W4378905636A5019938824 @default.
• W4378905636 hasAuthorship W4378905636A5019960092 @default.
• W4378905636 hasAuthorship W4378905636A5024055027 @default.
• W4378905636 hasAuthorship W4378905636A5037425566 @default.
• W4378905636 hasAuthorship W4378905636A5056439573 @default.
• W4378905636 hasAuthorship W4378905636A5057902086 @default.
• W4378905636 hasAuthorship W4378905636A5062458709 @default.
• W4378905636 hasAuthorship W4378905636A5068091489 @default.
• W4378905636 hasAuthorship W4378905636A5070381365 @default.
• W4378905636 hasAuthorship W4378905636A5074870098 @default.
• W4378905636 hasAuthorship W4378905636A5080579789 @default.
• W4378905636 hasAuthorship W4378905636A5091553385 @default.
• W4378905636 hasBestOaLocation W43789056361 @default.
• W4378905636 hasConcept C126322002 @default.
• W4378905636 hasConcept C188816634 @default.
• W4378905636 hasConcept C2776207728 @default.
• W4378905636 hasConcept C2778260677 @default.
• W4378905636 hasConcept C2779134260 @default.
• W4378905636 hasConcept C2779280984 @default.
• W4378905636 hasConcept C2780479503 @default.
• W4378905636 hasConcept C71924100 @default.
• W4378905636 hasConcept C90924648 @default.
• W4378905636 hasConceptScore W4378905636C126322002 @default.
• W4378905636 hasConceptScore W4378905636C188816634 @default.

• next